SCHEMBL24019692

SCHEMBL24019692

COc1ccc2[nH]c(C(=O)NC(C)C)cc2c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.77
ALDH1A1 P00352 6/20 0.77
MAPT P10636 5/20 0.77
PDGFRB P09619 2/20 0.68
PDGFRA P16234 2/20 0.68
FLT3 P36888 5/20 0.60
PYGL P06737 1/20 0.60
NPC1 O15118 4/20 0.59
RAB9A P51151 4/20 0.59
L3MBTL1 Q9Y468 2/20 0.59
MEN1 O00255 1/20 0.59
CYP1A2 P05177 1/20 0.59
CYP3A4 P08684 1/20 0.59
CYP2C9 P11712 1/20 0.59
TSHR P16473 1/20 0.59
KMT2A Q03164 1/20 0.59
HDAC6 Q9UBN7 1/20 0.59
LMNA P02545 1/20 0.59
HPGD P15428 1/20 0.59
HTT P42858 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8176164 0.89 KDM4E (0.66) KDM4EALDH1A1MAPTPDGFRBPDGFRA
SCHEMBL17149703 0.86 KDM4E (0.66) KDM4EALDH1A1MAPTPDGFRBPDGFRA
SCHEMBL9517979 0.85 PDGFRB (0.72) KDM4EALDH1A1MAPTPDGFRBPDGFRA
SCHEMBL19352730 0.84 KDM4E (0.64) KDM4EALDH1A1MAPTPDGFRBPDGFRA
SCHEMBL22518517 0.84 PDGFRB (0.70) KDM4EALDH1A1MAPTPDGFRBPDGFRA
SCHEMBL19352890 0.83 PYGL (0.64) KDM4EALDH1A1MAPTPDGFRBPDGFRA
SCHEMBL8176165 0.82 PDGFRB (0.56) KDM4EALDH1A1MAPTPDGFRBPDGFRA
SCHEMBL17321403 0.82 PDGFRB (0.72) KDM4EALDH1A1MAPTPDGFRBPDGFRA
SCHEMBL14845690 0.82 PIN1 (0.62) KDM4EALDH1A1MAPTPDGFRBPDGFRA
SCHEMBL2735968 0.82 FLT3 (0.61) KDM4EALDH1A1MAPTPDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2022-12-13 US disclosed
US-11174231-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2021-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11174231-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL KDM4E 2930/4885ALDH1A1 2252/4885MAPT 1905/4885
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL KDM4E 2930/4885ALDH1A1 2252/4885MAPT 1905/4885
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV KDM4E 3122/4885ALDH1A1 1863/4885MAPT 2314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.